• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Personalis Inc.

    5/6/25 4:12:22 PM ET
    $PSNL
    Medical Specialities
    Health Care
    Get the next $PSNL alert in real time by email
    8-K
    false 0001527753 0001527753 2025-05-06 2025-05-06
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 6, 2025

     

     

    Personalis, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   001-38943   27-5411038

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    6600 Dumbarton Circle

    Fremont, California

      94555
    (Address of Principal Executive Offices)   (Zip Code)

    (650) 752-1300

    Registrant’s Telephone Number, Including Area Code

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

     

      ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

      ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

      ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock, $0.0001 par value per share   PSNL   The Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 2.02

    Results of Operations and Financial Condition.

    On May 6, 2025, Personalis, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference.

    The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

     

    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit

    Number

      

    Description

    99.1    Press release of Personalis, Inc., dated May 6, 2025.
    104    Cover Page Interactive Data File (embedded within the inline XBRL document)


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

    Date: May 6, 2025   Personalis, Inc.
        By:  

    /s/ Aaron Tachibana

          Aaron Tachibana
          Chief Financial Officer and Chief Operating Officer
    Get the next $PSNL alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PSNL

    DatePrice TargetRatingAnalyst
    5/15/2025$6.00Buy
    Guggenheim
    3/17/2025$8.00Buy
    Canaccord Genuity
    2/6/2023$8.00Hold → Buy
    Needham
    2/6/2023Hold → Buy
    Needham
    2/25/2022$30.00 → $24.00Outperform
    Oppenheimer
    2/25/2022$30.00 → $18.00Buy
    Citigroup
    2/25/2022$50.00 → $38.00Buy
    HC Wainwright & Co.
    1/7/2022$27.00 → $23.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $PSNL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Personalis with a new price target

      Guggenheim initiated coverage of Personalis with a rating of Buy and set a new price target of $6.00

      5/15/25 8:13:23 AM ET
      $PSNL
      Medical Specialities
      Health Care
    • Canaccord Genuity initiated coverage on Personalis with a new price target

      Canaccord Genuity initiated coverage of Personalis with a rating of Buy and set a new price target of $8.00

      3/17/25 8:20:27 AM ET
      $PSNL
      Medical Specialities
      Health Care
    • Personalis upgraded by Needham with a new price target

      Needham upgraded Personalis from Hold to Buy and set a new price target of $8.00

      2/6/23 9:09:41 AM ET
      $PSNL
      Medical Specialities
      Health Care

    $PSNL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Personalis to Announce Second Quarter 2025 Financial Results

      Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, announced today that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly after the conc

      7/22/25 4:01:00 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on July 15, 2025, a non-qualified stock option to purchase an aggregate of 100,000 shares of its common stock to Personalis' new Vice President, Corporate Controller under Personalis' 2020 Inducement Plan. The 2020 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee, or non-employee director, of Personalis, as an inducement material to such individual's entering into employment with Personalis, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. Persona

      7/18/25 4:00:00 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • From Clinics to Cancer Labs, AI Is Unlocking a New $100B+ Era in Medicine

      Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, July 16, 2025 /PRNewswire/ -- Equity Insider News Commentary – Increased usage of AI in healthcare is predicted to not only save lives, but money too. However, the rollout of this industry-changing tech isn't going to happen overnight. The use of AI in healthcare is being pushed by the World Economic Forum (WEF) to provide in its words, a "healthier, more equitable world." A recent study published in Nature introduced a new "AI Affinity Score" designed to measure how comfortable patients are with artificial intelligence in their healthcare journey. The researchers found that factors like education and g

      7/16/25 6:35:00 PM ET
      $MSFT
      $PSNL
      $TEM
      $TVGN
      Computer Software: Prepackaged Software
      Technology
      Medical Specialities
      Health Care

    $PSNL
    Leadership Updates

    Live Leadership Updates

    See more
    • Personalis Appoints Former Roche Diagnostics and GRAIL Executive Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance

      Bhandari to drive regulatory strategies for minimal residual disease (MRD) cancer test Personalis achieves ISO 13485:2016 certification, attesting to its ability to deliver medical devices and related services of the highest quality Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomic testing for precision oncology, today announced the appointment of Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance. With over two decades of industry marketing and regulatory affairs experience, Ms. Bhandari will help the company navigate the regulatory requirements for the NeXT Personal® MRD test. She was most recently VP, Regulatory Affairs at GRAIL, and previously held se

      10/18/23 7:15:00 AM ET
      $PSNL
      Medical Specialities
      Health Care
    • Dr. Kenneth J. Widder Joins Personalis Board of Directors

      Personalis, Inc. (NASDAQ:PSNL) today announced that it has appointed Kenneth J. Widder, M.D., to its Board of Directors. Dr. Widder currently serves on the boards of QuidelOrtho Corporation and Evoke Pharma, Inc. and has over 40 years of experience working with biomedical companies, having previously served as a founder, director and/or CEO of Sydnexis, Inc., OrphoMed, Inc., Sytera, Inc., NovaCardia, Inc., Santarus, Inc., and Molecular Biosystems Inc., and as a general partner at LVP Life Science Ventures (formerly Latterell Venture Partners) and Windamere Venture Partners. He holds an M.D. from Northwestern University and trained in pathology at Duke University. "We are delighted to ha

      6/13/23 7:01:00 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • Personalis Announces CEO Retirement and Transition

      Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced that John West, co-founder, CEO and member of the board of directors of Personalis, notified the Company of his decision to retire as CEO and a director at the end of the calendar year. Mr. West has served in the DNA sequencing field for over forty years, and co-founded Personalis with four Stanford professors in 2011. Effective December 31, 2022, Aaron Tachibana, Personalis Chief Financial Officer, will serve as interim CEO and Christopher Hall, Personalis SVP and Head, Diagnostics Business, will be promoted to President. Mr. West will continue to serve as an advisor to the Board. "We th

      12/14/22 4:02:00 PM ET
      $PSNL
      Medical Specialities
      Health Care

    $PSNL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO AND COO Tachibana Aaron sold $6,390 worth of shares (1,291 units at $4.95), decreasing direct ownership by 0.78% to 165,099 units (SEC Form 4)

      4 - Personalis, Inc. (0001527753) (Issuer)

      5/20/25 5:53:11 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • SVP and Chief Legal Officer Moore Stephen Michael sold $8,291 worth of shares (1,675 units at $4.95), decreasing direct ownership by 3% to 64,200 units (SEC Form 4)

      4 - Personalis, Inc. (0001527753) (Issuer)

      5/20/25 5:51:51 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • CHIEF MEDICAL OFFICER AND EVP Chen Richard sold $4,504 worth of shares (910 units at $4.95), decreasing direct ownership by 0.72% to 124,957 units (SEC Form 4)

      4 - Personalis, Inc. (0001527753) (Issuer)

      5/20/25 5:50:02 PM ET
      $PSNL
      Medical Specialities
      Health Care

    $PSNL
    SEC Filings

    See more
    • SEC Form 8-K filed by Personalis Inc.

      8-K - Personalis, Inc. (0001527753) (Filer)

      7/9/25 4:17:50 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • Personalis Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Personalis, Inc. (0001527753) (Filer)

      5/19/25 4:10:07 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Personalis Inc.

      SCHEDULE 13G/A - Personalis, Inc. (0001527753) (Subject)

      5/14/25 10:39:48 AM ET
      $PSNL
      Medical Specialities
      Health Care

    $PSNL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Myers Woodrow A Jr bought $16,700 worth of shares (10,000 units at $1.67), increasing direct ownership by 62% to 26,116 units (SEC Form 4)

      4 - Personalis, Inc. (0001527753) (Issuer)

      3/5/24 5:15:53 PM ET
      $PSNL
      Medical Specialities
      Health Care

    $PSNL
    Financials

    Live finance-specific insights

    See more
    • Personalis to Announce Second Quarter 2025 Financial Results

      Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, announced today that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly after the conc

      7/22/25 4:01:00 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • Personalis Reports First Quarter 2025 Financial Results

      Clinical test volume of 2,184 increased 52% sequentially Pharma tests and services of $13.6 million increased 39% year-over-year Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter of 2025 ended March 31, 2025, and provided recent business highlights. Recent Business Highlights Delivered 2,184 total molecular tests in the first quarter of 2025, an increase of 52%, compared with 1,441 tests delivered in the fourth quarter of 2024, signifying increasing adoption of Personalis' technology Highlighted compelling performance of NeXT Personal for resectable Stage I-IV colorectal cancer (CRC) in a study

      5/6/25 4:01:00 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • Personalis to Announce First Quarter 2025 Financial Results

      Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, announced today that it will release its first quarter 2025 financial results on Tuesday, May 6, 2025. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly after the conclusio

      4/22/25 4:01:00 PM ET
      $PSNL
      Medical Specialities
      Health Care

    $PSNL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Personalis Inc.

      SC 13G/A - Personalis, Inc. (0001527753) (Subject)

      8/19/24 6:03:38 AM ET
      $PSNL
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Personalis Inc.

      SC 13G - Personalis, Inc. (0001527753) (Subject)

      7/26/24 12:56:21 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Personalis Inc.

      SC 13D/A - Personalis, Inc. (0001527753) (Subject)

      6/28/24 4:01:17 PM ET
      $PSNL
      Medical Specialities
      Health Care